Immune-Onc Therapeutics, Inc.

Immune-Onc is a clinical-stage company developing a novel class of myeloid checkpoint inhibitors. We believe myeloid checkpoints are the next frontier of immunotherapy for cancer. In collaboration with scientists, our research team is among the first in the world to target these immune suppressive pathways with novel therapies that have the potential to transform current treatment approaches for blood cancers and solid tumors.